Key result
The trivalent oral poliovirus vaccine is associated with a rare risk of paralytic poliomyelitis due to the potential of the live attenuated virus to revert to increased virulence.
Highlights the rare but significant risk of vaccine-associated paralytic poliomyelitis from the trivalent oral poliovirus vaccine due to viral reversion.
The global eradication of poliomyelitis has been targeted as a goal for the year 2000 by the World Health Organization,1 and naturally occurring poliomyelitis has already been eradicated from the Americas.2 Yet the occasional occurrence of paralytic poliomyelitis in association with the use of the trivalent oral poliovirus vaccine — either in vaccine recipients or in others who are in contact with recipients — remains a vexing problem. The basis for this rare breakthrough disease lies in the potential of the live attenuated virus in the vaccine to revert to increased virulence within the human gastrointestinal tract. Although such genetic . . .
No takes yet. Share an insight, caveat, or question.
Wright et al. (1995) conducted an editorial in Poliomyelitis. Trivalent oral poliovirus vaccine was evaluated. The trivalent oral poliovirus vaccine is associated with a rare risk of paralytic poliomyelitis due to the potential of the live attenuated virus to revert to increased virulence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: